Skip to main content

Advertisement

Table 3 Comparisons of pathological characteristics between diabetic group and non-diabetic group

From: Correlations of microRNA-124a and microRNA-30d with clinicopathological features of breast cancer patients with type 2 diabetes mellitus

Characteristic Diabetic group (n = 72) [%] Non-diabetic group (n = 144) [%] χ2 P value
T stage
 T1 16 (22.2) 36 (25.0) 0.809 0.667
 T2 35 (48.6) 74 (51.4)   
 T3 21 (29.2) 34 (23.6)   
Axillary lymph nodes
 Positive 45 (62.5) 75 (52.1) 2.109 0.146
 Negative 27 (37.5) 69 (47.9)   
Pathological types
 Invasive ductal carcinoma 66 (91.7) 136 (94.4) 0.890 0.828
 Invasive lobular carcinoma 3 (4.2) 3 (2.1)   
 Invasive papilloma 2 (2.8) 3 (2.1)   
 Mucinous adenocarcinoma 1 (1.4) 2 (1.4)   
Tumor stage
 I 4 (5.6) 19 (13.2) 2.966 0.227
 II 27 (37.5) 51 (35.4)   
 III 41 (56.9) 74 (51.4)   
Histological grade
 WHO I 5 (6.9) 9 (6.2) 2.099 0.350
 WHO II 42 (58.3) 98 (68.1)   
 WHO III 25 (34.7) 37 (25.7)   
Lymph node metastasis
 Positive 45 (62.5) 55 (38.2) 11.410 <0.001
 Negative 27 (37.5) 89 (61.8)   
ER
 Positive 42 (58.3) 88 (61.1) 0.155 0.694
 Negative 30 (41.7) 56 (38.9)   
PR
 Positive 40 (55.6) 91 (63.2) 1.174 0.279
 Negative 32 (44.4) 53 (36.8)   
Her-2
 Positive 25 (34.7) 66 (458) 2.431 0.119
 Negative 47 (65.3) 78 (54.2)   
P-gp
 Positive 60 (83.3) 121 (84.0) 0.017 0.896
 Negative 12 (16.7) 23 (16.0)   
Topo-II
 Positive 64 (88.9) 132 (91.7) 0.441 0.507
 Negative 8 (11.1) 12 (8.3)   
Gst-π
 Positive 39 (54.2) 70 (48.6) 0.593 0.441
 Negative 33 (45.8) 74 (51.4)   
  1. Diabetic group, breast cancer patients with type 2 diabetes mellitus; non-Diabetic group, breast cancer patients without type 2 diabetes mellitus
  2. WHO World Health Organization, ER estrogen receptor, PR progesterone receptor, Her-2 human epithelial growth factor receptor 2, P-gp P-glyprotein, Topo-II topoisomerase II, Gst-π glatocnine-S-tranferase-π